Author

Vasanthi S. Viswanathan

Primary ORCID profile (0000-0001-9878-3629 · 3 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Vasanthi S. ViswanathaniD3 papers

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Amy A. Deik· 1 shared Bridget K. WagneriD· 1 shared Clary B. Clish· 1 shared Elizaveta S. Leshchiner· 1 shared Haoxin LiiD· 1 shared Jesse S. BoehmiD· 1 shared John Doench· 1 shared John K. Eaton· 1 shared

Activity by Year

2018-2018 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Amy A. Deik

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintAug 9, 2018

HIF-2α drives an intrinsic vulnerability to ferroptosis in clear cell renal cell carcinoma

Yilong Zou, Michael J. Palte, Amy A. Deik…·Stuart L. Schreiber

This paper identifies a vulnerability in clear-cell renal cell carcinoma cells to ferroptosis induced by GPX4 inhibition, driven by the HIF-2-HILPDA pathway and PUFA-lipid enrichment.

DOI 10.1101/388041

humanproteomics